Case Study: Non-secretory Multiple Myeloma with Eosinophilia - Diagnostic Hurdles and a Comprehensive Literature Review

• by Jirui Zhong, Xikun Liu, Jiduo Liu, Shanshan Xiao, Xuekui Gu, Zenghui Liu

• April 22, 2026

Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside

• by Domenico Galati, Zohreh Amoozgar, Ling Ni

• May 1, 2026

Infection incidence, timing, and predictors in newly diagnosed multiple myeloma: a real-world retrospective cohort study

• by Ozlem Candan, Narmin Naghizada, Tekin Tuncel, Beyza Melek Palaz, Mustafa Alperen Tunc, Derya Demirtas, Ahmet Mert Yanik, Arda Bayar, Secil Salim, Fatma Temiz, Ceren Uzunoglu Guren, Fatma Arıkan, Meral Ulukoylu Menguc, Asu Fergun Yilmaz, Isik Atagunduz, Zekaver Odabası, Tayfur Toptas, Ayse Tulin Tuglular

• May 14, 2026

A Comprehensive Review of Monoclonal Gammopathy of Undetermined Significance

Approximately 3% to 4% of the population over the age of 50 is diagnosed with monoclonal gammopathy of undetermined significance (MGUS). It carries a lifelong risk of progression to multiple myeloma and lymphoma, requiring risk-adapted monitoring by multidisciplinary teams.

• by Kimberly Noonan, Kevin Brigle, Charise Gleason, Carrie Bellerive, Mary Steinbach, Deborah Doss

• March 4, 2026

• 17 min